ArticleJournal of clinical bioinformatics2013
MicroRNAs: an emerging science in cancer epigenetics.
Article in Journal of clinical bioinformatics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of MicroRNAs in Hemorrhagic Neurovascular Disease: Cerebral Cavernous Malformations as a Paradigm.International journal of molecular sciences · 2025Pooled it
- Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations.Translational stroke research · 2025Article
- An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.Genes · 2023Review
- Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.Scientific reports · 2021Article
- Exploring the Triple Interaction between the Host Genome, the Epigenome, and the Gut Microbiome in Type 1 Diabetes.International journal of molecular sciences · 2020Review
- MiR-425 Promotes Migration and Invasion in Bladder Cancer by Targeting Dickkopf 3.Journal of Cancer · 2020Article
- Non-Nutritive Sweeteners and Their Implications on the Development of Metabolic Syndrome.Nutrients · 2019Review
- miR-410 acts as an oncogene in colorectal cancer cells by targeting dickkopf-related protein 1 via the Wnt/β-catenin signaling pathway.Oncology letters · 2019Article
- Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention.Environmental health and preventive medicine · 2018Review
- Targetome Analysis Revealed Involvement of MiR-126 in Neurotrophin Signaling Pathway: A Possible Role in Prevention of Glioma Development.Cell journal · 2018Article
- Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides.BMC molecular biology · 2018Article
- miR‑539 suppresses proliferation and induces apoptosis in renal cell carcinoma by targeting high mobility group A2.Molecular medicine reports · 2018Article
- Current Insights into Oral Cancer Epigenetics.International journal of molecular sciences · 2018Review
- MiR-543 promotes cell proliferation and metastasis of renal cell carcinoma by targeting Dickkopf 1 through the Wnt/β-catenin signaling pathway.Journal of Cancer · 2018Article
- The Plasticizer Bisphenol A Perturbs the Hepatic Epigenome: A Systems Level Analysis of the miRNome.Genes · 2017Article
- Epigenetics of human diseases and scope in future therapeutics.Journal of Taibah University Medical Sciences · 2017Review
- Diet phytochemicals and cutaneous carcinoma chemoprevention: A review.Pharmacological research · 2017Review
- Genome-Wide Sequencing Reveals MicroRNAs Downregulated in Cerebral Cavernous Malformations.Journal of molecular neuroscience : MN · 2017Article
- Overexpression of miR-140 Inhibits Proliferation of Osteosarcoma Cells via Suppression of Histone Deacetylase 4.Oncology research · 2017Article
- New Insight into microRNA Functions in Cancer: Oncogene-microRNA-Tumor Suppressor Gene Network.Frontiers in molecular biosciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
MicroRNAs (miRNAs) are remarkable molecules that appear to have a fundamental role in the biology of the cell. They constitute a class of non-protein encoding RNA molecules which have now emerged as key players in regulating the activity of mRNA. miRNAs are small RNAmolecules around 22 nucleotides in length, which affect the activity of specific mRNA, directly degrading it and/or preventing its translation into protein. The science of miRNAs holds them as candidate biomarkers for the early detection and management of cancer. There is also considerable excitement for the use of miRNAs as a novel class of therapeutic targets and as a new class of therapeutic agents for the treatment of cancers. From a clinical perspective, miRNAs can induce a number of effects and may have a diverse application in biomedical research. This review highlights the general mode of action of miRNAs, their biogenesis, the effect of diet on miRNA expression and the impact of miRNAs on cancer epigenetics and drug resistance in various cancers. Further we also provide emphasis on bioinformatics software which can be used to determine potential targets of miRNAs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.